Western Blotting (WB), ELISA, Immunoprecipitation (IP), Neutralization (Neut)
Marke
BD Pharmingen™
Produktmerkmale
The BVD2-23B6 antibody reacts with human granulocyte/macrophage - colony stimulating factor (GM-CSF). The immunogen used to generate the BVD2-23B6 hybridoma was E. coli-expressed recombinant human GM-CSF. This is a neutralizing antibody. This antibody is routinely tested by ELISA analysis. Other applications were tested during antibody development only or reported in the literature.
BD Pharmingen™ Purified Rat Anti-Human GM-CSF - Purified - Clone BVD2-23B6 - Isotype Rat IgG2a - Reactivity Hu - 0.5 mg
Aufreinigung
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
Store undiluted at 4°C.
Abrams, Roncarolo, Yssel, Andersson, Gleich, Silver: "Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples." in: Immunological reviews, Vol. 127, Issue 9-10, pp. 5-24, (1992) (PubMed).
Kita, Ohnishi, Okubo, Weiler, Abrams, Gleich: "Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils." in: The Journal of experimental medicine, Vol. 174, Issue 3, pp. 745-8, (1991) (PubMed).
Bacchetta, de Waal Malefijt, Yssel, Abrams, de Vries, Spits, Roncarolo: "Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 144, Issue 3, pp. 902-8, (1990) (PubMed).